AI-ML Drug Discovery and Development Summit

Memo

The 3rd Annual AI-ML: Drug Discovery and Development Summit is the industry's definitive guide to translating the wealth of tech available to successful, efficacious and efficient RandD processes. With 3 days of real-world case studies, this summit will provide the roadmap to augmented RandD decision making with reduced failure rates, increased speed and improved margins. This year's summit will take a deeper look at: - Target, pathway and molecule selection - identifying which will treat individual disease indications better - Predictive preclinical models - knowing from the beginning how drug candidates will react when administered to in vivo and in vitro models - Identification of the patients who will react best to the treatment with minimal side effects for a guaranteed successful clinical trial Join 80+ like-minded peers to overhaul RandD and reflect on the lessons learned from the successes and mistakes made from a year of implementation and utilization. Walk away with a blueprint for more accurate, more efficient and more effective RandD processes. Download the Full Event Guide to get a taste of the real-world case studies you'll be joining at the conference. URLs:Tickets: https://go.evvnt.com/553976-1?pid=5569 Brochure: https://go.evvnt.com/553976-3?pid=5569  Date and Time: On Monday February 24, 2020 at 8:00 am ends Wednesday February 26, 2020 at 4:00 pm Venue details: DoubleTree by Hilton Hotel San Diego - Mission Valley, 7450 Hazard Center Drive, San Diego, California, 92108, United States Prices:Conference + 2 Workshops Industry: USD 3597.00,Conference + 1 Workshop Industry: USD 3098.00,Conference Only Industry: USD 2599.00,Conference + 2 Workshops Acadmic: USD 2597.00,Conference + 1 Workshop Acadmic: USD 2198.00,Conference Only Acadmic: USD 1799.00 Speakers: Daniel Bozinov, Senior Director, Head of ECD Informatics, Genentech, Tudor Oprea, Professor - Medicine and Chief of Translational Informatics Division and Internal Medicine, University of New Mexico, Shruthi Bharadwaj, Scientist, Novartis, Sándor Szalma, Senior Director - Biomedical Informatics and Global Head of Computational Biology Biomedical Informatics, Takeda, Deirdre Olynick, ATOM, Director - Business Development and Operations, University of Califorina, San Francisco, Bowen Liu, Candidate, Pande Group, Stanford University, Liling Warren, Associate Director, Lead Translational Statistics, Teva Pharmaceuticals, Marcin Grotthuss, Computational Biologist, The Broad Institute of MIT and Harvard, Lina Nilsson, Senior Director - Data Science Product, Recursion Pharmaceuticals, Huanyu Zhou, Senior Director and Head Translational and Non-clinical Statistics, Teva Pharmaceuticals, Birgit Schoeberl, Global Head of Modeling, Simulation and Pharmacokinetics Sciences, Novartis, Andrew Weber, Research Director, ATOM Consortium, Brandon Allgood, Chief Technology Officer, Numerate, Marc Bailly, Associate Principal Scientist, Merck, Gerald Higgins, M.D. P.hD. Research Professor of Computational Medicine and Bioinformatics, University of Michigan, Kelly Myers, Chief Technology Officer, FH Foundation, Alex Aronov, Senior Director and Head of Data Science, Data Strategy and Solutions, Vertex Pharmaceuticals, Guido Lanza, President and Chief Executive Officer, Numerate, Ronald Dorenbos, Associate Director, Materials and Innovation, Takeda